INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study is to determine the specific applications and forecast global market demand for synthetic biology products over a 5-year period from 2008 to 2013. Our particular interest is to characterize and quantify the synthetic biology products market potential by technology and end-use market segments. We also analyze the synthetic biology industry structure, competitors, and intellectual property landscape.
Synthetic biology products reviewed in this report include enabling technologies, biologic components, integrated systems, and enabled products.
Our key objective is to present a comprehensive analysis of the emerging synthetic biology industry, with an emphasis on products and technologies that are commercially important in the 2008 to 2013 time period. Market segments with rapid growth rates are highlighted. This analysis provides a quantitative basis and market context for companies to make strategic choices about participation in the synthetic biology industry. The study will be particularly useful to companies supplying synthetic genes, oligonucleotides, DNA sequencing instruments, biofuels, specialty chemicals, pharmaceuticals, vaccines, microfluidics, and life sciences tools.
REASONS FOR DOING THE STUDY
Synthetic biology is a rapidly emerging biotechnology discipline with a wide range of applications. Despite its emerging status, synthetic biology provides a significant number of near-term commercial opportunities, and the list of new products and applications is continuously growing. These applications include specialty chemicals, enzymes, synthetic genes and other DNA parts, pharmaceuticals, biofuels, and chassis microorganisms.
It is important for companies in industries affected by the developments in synthetic biology to sort through the many potential applications to identify near-term commercial opportunities for product development focus. This report allows companies to prioritize product opportunities, establishing a solid framework for strategic planning.
Synthetic biology encompasses a wide range of industries, including life science tools, biotechnology, pharmaceuticals, energy, and chemicals. Because of its wide scope, synthetic biology will play an important role in the future of the industrial economy of the early 21st century.
Ongoing advances in enabling technologies, such as microfluidics, DNA synthesis, DNA sequencing, and bioinformatics, as well as a need for renewable feedstocks, are driving the growth of synthetic biology. Rapid developments in these multidisciplinary fields promise to advance the synthetic biology industry and create unique market opportunities. This report analyzes these trends and their impact on the future markets for synthetic biology products.
Based on these market and technology dynamics, it is especially timely to examine the future synthetic biology markets.
INTENDED AUDIENCE
We have compiled a study of existing and future synthetic biology products and technologies that will be commercially important in the main end-user segments of life science research, pharmaceuticals, energy, and chemicals.
We present markets by end-use segment (R&D, biotech/pharmaceuticals, energy and chemicals) and by technology (enabling technologies, biologic parts, integrated systems, and enabled products). Key market segments include synthetic genes, chassis organisms, biofuels, specialty chemicals, and pharmaceuticals.
We present synthetic biology technologies, growth-driving forces, market applications, industry structure and competitive dynamics, companies and industry alliances, future market potential, and product sales forecasts for the period 2008 through 2013. We project the future use of synthetic biology products in the main end-user segments and by technology.
This report will be of particular interest to pharmaceuticals, chemicals, enzymes, energy, biotechnology, and nanobiotechnology companies, as well as suppliers of genomics tools, DNA synthesis, and DNA sequencing companies. It will also be of high interest to professionals within regulatory agencies to understand the scope and pace of synthetic biology technologies as they reach the market.
SCOPE OF REPORT
The study scope includes the synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, bioinformatics), and enabled technologies (biofuels, specialty chemicals, pharmaceuticals) that are already commercial or forecast to be commercialized within the next 5 years.
We analyze key synthetic biology technologies and products to determine present and future market status, and forecasted growth from 2008 through 2013. We also discuss strategic alliances, industry structures, competitive dynamics, patenting situation, and market-driving forces.
BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, bioenergy suppliers, and specialty chemicals. The role of key strategic alliances from 2006 through 2009 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, chassis organisms, and metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and the main companies in these fields are highlighted.
METHODOLOGY
BCC surveys key users and producers in each of the end-user market segments and technology fields that will be commercially important during the next 5 years. Discussions with industry thought leaders, as well as secondary market research was performed.
Based on our analysis, we project the future applications of synthetic biology technologies in the major end-user market segments and by technology type, and forecast sales revenues for 2008 through 2013.
INFORMATION SOURCES
BCC surveyed leading synthetic biology, biotechnology, pharmaceutical, chemical, and energy companies to obtain data for this study. Included were life science research tools, drug, biotechnology, DNA synthesis and sequencing, and microfluidics firms, as well as leading life science research institutions. We also obtained inputs from leading academic and industry thought leaders. Data from secondary sources included industry, trade, and government publications.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; and Biologic Imaging Reagent: Future Technologies and Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Master of Business Administration.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Report Code: BIO066A, Published: June 2009, Analyst: John Bergin
